Evidence map›Paper›PMID 40209948›Full record

ArticleThe Journal of biological chemistry2025

Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients.

Teresa W-M Fan, Jing Yan, Carlos Frederico L Goncalves, Jahid M M Islam, Penghui Lin, Mohamed M Y Kaddah, Richard M Higashi, Andrew N Lane, Xiaoqin Wang, Caigang Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Teresa W-M FanCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA. Electronic address: twmfan@gmail.com.
Jing YanF. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky, USA.
Carlos Frederico L GoncalvesF. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky, USA.
Jahid M M IslamCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Penghui LinCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Mohamed M Y KaddahCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA; Pharmaceutical and Fermentation Industries Development Center, City of Scientific Research and Technological Applications, Alexandria, Egypt.
Richard M HigashiCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Andrew N LaneCenter for Environmental and Systems Biochemistry (CESB), Department of Toxicology and Cancer Biology, and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Xiaoqin WangDepartment of Radiology, University of Kentucky, Lexington, Kentucky, USA.
Caigang ZhuF. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky, USA. Electronic address: caigang.zhu@uky.edu.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Binhua P Zhou · 2017 to 2026
$25.0M
Non-destructive optical spectroscopic assay for high-throughput metabolic characterization of in vitro cell models and patient-derived organoidsR21EB032515 · NIBIB · UNIVERSITY OF KENTUCKY · PI ZHU, CAIGANG · 2022 to 2024
$597k
NCI NIH HHS P30 CA177558NIBIB NIH HHS R21 EB032515NIGMS NIH HHS P20 GM121327
6 · The paper itself

Abstract

Patient-derived organotypic tissue cultures (PD-OTC) are unique models for probing cancer metabolism and therapeutic responses. They retain patient tissue architectures/microenvironments that are difficult to recapitulate while affording comparison of cancer (CA) versus matched noncancer (NC) tissue responses to treatments. We have developed a long-term culturing method for fresh and cryopreserved PD-OTC of breast cancer patients bearing invasive ductal carcinoma. Five PD-OTC came from patients with treatment-naïve primary ER

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastTissue Culture TechniquesFemaleGlycolysisHumansMetabolic Reprogrammingbreast cancergluconeogenesisnucleotide synthesispatient-derived organotypic tissue culturesreverse phase protein arraystable isotope-resolved metabolomicstumor metabolic reprogramming

Identifiers

PMID40209948
PMCPMC12137166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.